LINC01118: A Long Intergenic Non-Protein-Coding RNA (G388948)

Target Name: LINC01118

NCBI ID: G388948

LINC01118

Other Name(s): long intergenic non-protein coding RNA 1118 | Long intergenic non-protein coding RNA 1118

LINC01118: A Long Intergenic Non-Protein-Coding RNA

Introduction

LINC01118 is a long non-protein-coding RNA (lncRNA) molecule that has been identified in various organisms, including humans. It is characterized by its unique 3'-end covered with a tail of approximately 1,100 nucleotides, making it resistant to staining There are expression patterns in the plasma that are different from other lncRNAs. This characteristic makes LINC01118 of great value in genetic informatics research, and may also become a potential drug target or biomarker.

Secondary structure of LINC01118

The RNA sequence of LINC01118 consists of 19,221 nucleotides. Its open reading frame (ORF) consists of a nucleotide sequence whose conservation is highly similar in multiple species, but there is an extra exon in humans. The ORF of LINC01118 is highly conserved in all known species, so it may be conserved from multiple primates or other eukaryotes.

Three-level structure of LINC01118

Although the ORF of LINC01118 is highly similar in different species, its secondary structure differs in different species. In humans, the secondary structure of LINC01118 appears as an RNA band with a length of 112 nucleotides, and its 3'-end contains a special domain. This domain consists of a highly conserved nucleotide sequence of 44 nucleotides.

Biological functions of LINC01118

The functionality of LINC01118 is currently under investigation. Research shows that LINC01118 plays an important biological role in gene expression and regulation. The expression pattern of LINC01118 changes during various physiological and pathological processes, such as cell proliferation, differentiation, and tumor formation. In addition, the expression level of LINC01118 is also related to a variety of diseases and drug responses, such as neurodegenerative diseases, cancer, and immune disorders.

Pharmacological significance of LINC01118

The pharmacological significance of LINC01118 lies in its potential as a new drug target. Since LINC01118 changes in a variety of physiological and pathological processes, it may have potential value in treating a variety of diseases. The expression pattern of LINC01118 is associated with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as immune dysregulation diseases, such as autoimmune diseases and inflammation-related diseases. Therefore, LINC01118 may become a new drug target for the treatment of these diseases.

LINC01118 also has high expression levels and variability, so it may also be a potential candidate molecule as a biomarker. By detecting the expression level and variability of LINC01118, we can better understand the gene expression regulation process in organisms and explore the molecular mechanisms related to the occurrence and development of diseases.

in conclusion

LINC01118 is a unique lncRNA molecule with conserved sequence and secondary structure. The expression pattern of LINC01118 changes during various physiological and pathological processes and may be related to diseases and drug responses. Therefore, LINC01118 may become a new drug target or biomarker for the treatment of various diseases. Future studies will delve into the biological functions and pharmacological significance of LINC01118 to better understand its role in gene expression and disease.

Protein Name: Long Intergenic Non-protein Coding RNA 1118

The "LINC01118 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01118 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets